ImmunityBio (NASDAQ:IBRX) Shares Gap Down - Should You Sell?

Key Points

Error: One or more errors occurred.

ImmunityBio, Inc. (NASDAQ:IBRX - Get Free Report)'s stock price gapped down prior to trading on Wednesday . The stock had previously closed at $6.48, but opened at $6.27. ImmunityBio shares last traded at $6.1450, with a volume of 36,049,692 shares changing hands.

Key Headlines Impacting ImmunityBio

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: FDA outlined a clear resubmission path for ANKTIVA (nogapendekin alfa inbakicept) in BCG‑unresponsive papillary NMIBC; ImmunityBio says it will submit additional information within ~30 days after the Type B end‑of‑phase meeting — a concrete regulatory route that materially reduces near‑term binary risk. ImmunityBio Advances Regulatory Discussions with FDA on Potential Resubmission Path for ANKTIVA®
• Positive Sentiment: Market reaction: multiple outlets report the stock jumped sharply (mid‑January moves of ~15–20%) after the FDA meeting news, reflecting investor belief that a resubmission could unlock labeled use in an oncology market — the surge has increased liquidity and attention on the ticker. ImmunityBio Stock Soars on FDA Talks for Anktiva sBLA Resubmission
• Positive Sentiment: Analyst/upside notes: HC Wainwright raised long‑range FY2030 EPS estimates materially (A. Maldonado: $0.68 FY2030), and at least one boutique shop reaffirmed a buy with a high $24 price target — these calls support a bullish narrative and can lift sentiment among growth investors.
• Neutral Sentiment: Momentum: coverage highlights the stock hitting fresh highs and an extended multi‑day rally; that’s bullish signal‑wise but increases the chance of short‑term pullbacks as traders take profits. ImmunityBio (IBRX) rockets on 12th day, hits fresh high
• Neutral Sentiment: Bull case discussion: independent bull analyses and commentary outline multiple upside scenarios tied to ANKTIVA label expansion and other pipeline assets — useful for longer‑term thesis but dependent on regulatory and commercial execution. ImmunityBio, Inc. (IBRX): A Bull Case Theory
• Negative Sentiment: Risk/valuation and sell‑side caution: some sector pieces flagged IBRX among names to avoid given extreme momentum and event‑driven volatility; the company still faces clinical, regulatory and commercialization risk, and the recent run has left the share price stretched versus fundamentals. Top 3 Health Care Stocks You May Want To Dump In January

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on IBRX shares. Jefferies Financial Group lifted their price objective on ImmunityBio from $8.00 to $9.00 and gave the company a "buy" rating in a report on Friday, December 12th. Weiss Ratings reiterated a "sell (e+)" rating on shares of ImmunityBio in a research report on Monday, December 29th. D. Boral Capital reaffirmed a "buy" rating and set a $24.00 price target on shares of ImmunityBio in a research note on Tuesday. Finally, Piper Sandler raised their price objective on shares of ImmunityBio from $5.00 to $7.00 and gave the company an "overweight" rating in a research note on Tuesday. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $12.00.

ImmunityBio Stock Up 5.9%

The firm has a market capitalization of $6.76 billion, a PE ratio of -16.79 and a beta of 0.03. The business's fifty day moving average price is $2.44 and its 200 day moving average price is $2.49.

ImmunityBio (NASDAQ:IBRX - Get Free Report) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.03. The business had revenue of $32.06 million during the quarter, compared to analyst estimates of $31.88 million. As a group, sell-side analysts forecast that ImmunityBio, Inc. will post -0.92 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Slow Capital Inc. acquired a new position in shares of ImmunityBio in the 3rd quarter valued at about $25,000. Envision Financial Planning LLC purchased a new stake in ImmunityBio during the second quarter worth approximately $28,000. Summit X LLC acquired a new stake in shares of ImmunityBio in the second quarter worth $28,000. Diversify Advisory Services LLC acquired a new position in shares of ImmunityBio during the 2nd quarter valued at $27,000. Finally, Truist Financial Corp purchased a new stake in ImmunityBio during the 3rd quarter worth $27,000. 8.58% of the stock is owned by hedge funds and other institutional investors.

About ImmunityBio

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.